Canada inks $56M deal with Bavarian Nordic (BAVA) for monkeypox vaccine

By - Reuters


  • Canada has signed a $56 million contract with a Danish biotechnology company named Bavarian Nordic.
  • The deal is for Bavarian Nordic’s smallpox vaccine, which has been approved for use against monkeypox in the country.
  • The deliveries are set to start next year.

Danish biotechnology company Bavarian Nordic (CPH: BAVA) said on Tuesday it had signed a $56 million contract with Canada for its smallpox vaccine, which is also approved for use against monkeypox in the country, with deliveries starting next year.

Also read: ICYMI, investors! Best 10 TSX stocks for June 2022

Also read: Tonix (TNXP) stock soars after monkeypox-related patent. Buy call?

"In parallel, Bavarian Nordic continues to secure contracts with other countries, including Denmark, but also countries outside Europe, to supply the vaccine to mitigate the current monkeypox outbreak", said the firm.

© 2022 Kalkine Media®

Bavarian will also host an investor call later on Tuesday at 1500 CET (1300 GMT).

Open in the App